|
ViziLite® Plus oral lesion identification and marking system
The newest tool in the fight against oral disease is the
ViziLite® Plus oral lesion identification and marking system.
ViziLite® Plus, from Zila Pharmaceuticals, combines the oral screening
technology of ViziLite, an advanced chemiluminescent light technology to
help detect oral abnormalities, with TBlue630™. TBlue630 is the only
patented pharmaceutical-grade form of toluidine blue that has been cleared
by the FDA for use in marking lesions identified during a ViziLite
examination.
ViziLite Plus makes oral screening more comprehensive than ever before and
is indicated for use in individuals at increased risk of oral cancer. If
ViziLite reveals an abnormality, TBlue630 can be used to mark suspicious
lesions for further evaluation.
VIZILITE PLUS PRODUCT PHOTOS
ViziLite Plus
Supplemental Pack
How ViziLite Plus Works
ViziLite Plus with TBlue630 is an oral lesion identification and
marking system that is used as an adjunct to the conventional head and
neck examination. It is comprised of a chemiluminescent light source (ViziLite)
to improve the identification of lesions and a blue phenothiazine dye to mark
those lesions identified by ViziLite. ViziLitePlus with TBlue630 is
designed to be used in a patient population at increased risk for oral cancer.
ViziLite Oral
Lesion Identification System
In clinical trials involving 13,000 female patients, abnormal squamous
epithelium in the cervical complex appears acetowhite after rinsing with a
dilute acetic acid solution and viewed under chemiluminescent light (Speculite®).
Similarly in the oral cavity, after rinsing with a dilute acetic acid solution,
abnormal squamous epithelium tissue will appear acetowhite when viewed under
ViziLite's diffuse low-energy wavelength light. Normal epithelium will absorb
the light and appear dark. ViziLite can assist a dentist or hygienist in
identifying an abnormality in the oral cavity.
 
TBlue630
Oral Lesion Marking System
TBlue630 is a patented, pharmaceutical-grade toluidine blue-based
metachromatic dye. It is used to further evaluate and closely monitor changes
in ViziLite-identified lesions. It has been proposed that living cells will
differentially accumulate toluidine blue based on parameters related to
metabolic activity. TBlue630, packaged in an easy to use 3-swab
system, provides the deep blue staining that allows ViziLite-identified lesions
to be seen clearly under normal light.
ViziLite Plus Usage Images
Image 1
Image 2
Image 3
Image 4
Image 5
Image 6
Visit the makers of ViziLite for more details
|
